Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice.

For proper cholesterol metabolism, normal expression and function of scavenger receptor class B type I (SR-BI), a high-density lipoprotein (HDL) receptor, is required. Among the factors that regulate overall cholesterol homeostasis and HDL metabolism, the nuclear farnesoid X receptor plays an import...

Full description

Bibliographic Details
Main Authors: Andrea Leiva, Susana Contreras-Duarte, Ludwig Amigo, Esteban Sepúlveda, Mauricio Boric, Verónica Quiñones, Dolores Busso, Attilio Rigotti
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5598962?pdf=render
_version_ 1818274456218370048
author Andrea Leiva
Susana Contreras-Duarte
Ludwig Amigo
Esteban Sepúlveda
Mauricio Boric
Verónica Quiñones
Dolores Busso
Attilio Rigotti
author_facet Andrea Leiva
Susana Contreras-Duarte
Ludwig Amigo
Esteban Sepúlveda
Mauricio Boric
Verónica Quiñones
Dolores Busso
Attilio Rigotti
author_sort Andrea Leiva
collection DOAJ
description For proper cholesterol metabolism, normal expression and function of scavenger receptor class B type I (SR-BI), a high-density lipoprotein (HDL) receptor, is required. Among the factors that regulate overall cholesterol homeostasis and HDL metabolism, the nuclear farnesoid X receptor plays an important role. Guggulsterone, a bioactive compound present in the natural product gugulipid, is an antagonist of this receptor. This natural product is widely used globally as a natural lipid-lowering agent, although its anti-atherogenic cardiovascular benefit in animal models or humans is unknown. The aim of this study was to determine the effects of gugulipid on cholesterol homeostasis and development of mild and severe atherosclerosis in male mice. For this purpose, we evaluated the impact of gugulipid treatment on liver histology, plasma lipoprotein cholesterol, endothelial function, and development of atherosclerosis and/or ischemic heart disease in wild-type mice; apolipoprotein E knockout mice, a model of atherosclerosis without ischemic complications; and SR-B1 knockout and atherogenic-diet-fed apolipoprotein E hypomorphic (SR-BI KO/ApoER61h/h) mice, a model of lethal ischemic heart disease due to severe atherosclerosis. Gugulipid administration was associated with histological abnormalities in liver, increased alanine aminotransferase levels, lower hepatic SR-BI content, hypercholesterolemia due to increased HDL cholesterol levels, endothelial dysfunction, enhanced atherosclerosis, and accelerated death in animals with severe ischemic heart disease. In conclusion, our data show important adverse effects of gugulipid intake on HDL metabolism and atherosclerosis in male mice, suggesting potential and unknown deleterious effects on cardiovascular health in humans. In addition, these findings reemphasize the need for rigorous preclinical and clinical studies to provide guidance on the consumption of natural products and regulation of their use in the general population.
first_indexed 2024-12-12T22:14:09Z
format Article
id doaj.art-02892ecd64c04ab79e54c19ce19431ad
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-12T22:14:09Z
publishDate 2017-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-02892ecd64c04ab79e54c19ce19431ad2022-12-22T00:10:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01129e018428010.1371/journal.pone.0184280Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice.Andrea LeivaSusana Contreras-DuarteLudwig AmigoEsteban SepúlvedaMauricio BoricVerónica QuiñonesDolores BussoAttilio RigottiFor proper cholesterol metabolism, normal expression and function of scavenger receptor class B type I (SR-BI), a high-density lipoprotein (HDL) receptor, is required. Among the factors that regulate overall cholesterol homeostasis and HDL metabolism, the nuclear farnesoid X receptor plays an important role. Guggulsterone, a bioactive compound present in the natural product gugulipid, is an antagonist of this receptor. This natural product is widely used globally as a natural lipid-lowering agent, although its anti-atherogenic cardiovascular benefit in animal models or humans is unknown. The aim of this study was to determine the effects of gugulipid on cholesterol homeostasis and development of mild and severe atherosclerosis in male mice. For this purpose, we evaluated the impact of gugulipid treatment on liver histology, plasma lipoprotein cholesterol, endothelial function, and development of atherosclerosis and/or ischemic heart disease in wild-type mice; apolipoprotein E knockout mice, a model of atherosclerosis without ischemic complications; and SR-B1 knockout and atherogenic-diet-fed apolipoprotein E hypomorphic (SR-BI KO/ApoER61h/h) mice, a model of lethal ischemic heart disease due to severe atherosclerosis. Gugulipid administration was associated with histological abnormalities in liver, increased alanine aminotransferase levels, lower hepatic SR-BI content, hypercholesterolemia due to increased HDL cholesterol levels, endothelial dysfunction, enhanced atherosclerosis, and accelerated death in animals with severe ischemic heart disease. In conclusion, our data show important adverse effects of gugulipid intake on HDL metabolism and atherosclerosis in male mice, suggesting potential and unknown deleterious effects on cardiovascular health in humans. In addition, these findings reemphasize the need for rigorous preclinical and clinical studies to provide guidance on the consumption of natural products and regulation of their use in the general population.http://europepmc.org/articles/PMC5598962?pdf=render
spellingShingle Andrea Leiva
Susana Contreras-Duarte
Ludwig Amigo
Esteban Sepúlveda
Mauricio Boric
Verónica Quiñones
Dolores Busso
Attilio Rigotti
Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice.
PLoS ONE
title Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice.
title_full Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice.
title_fullStr Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice.
title_full_unstemmed Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice.
title_short Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice.
title_sort gugulipid causes hypercholesterolemia leading to endothelial dysfunction increased atherosclerosis and premature death by ischemic heart disease in male mice
url http://europepmc.org/articles/PMC5598962?pdf=render
work_keys_str_mv AT andrealeiva gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT susanacontrerasduarte gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT ludwigamigo gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT estebansepulveda gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT mauricioboric gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT veronicaquinones gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT doloresbusso gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT attiliorigotti gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice